Perioperative Risks of Fioricet

Primary Perioperative Concerns

The Society for Perioperative Assessment and Quality Improvement (SPAQI) recommends holding butalbital on the day of operation due to its sedative properties that compound CNS depression from anesthetic agents, creating additive risks 1
Butalbital enhances CNS depression when combined with general anesthetics, producing profound sedation and potentially life-threatening respiratory depression 1
The combination of butalbital with perioperative opioids can lead to respiratory depression requiring emergent intervention, including potential intubation 1
Butalbital can impair psychomotor recovery needed after general anesthesia, reducing patients' ability to ambulate, eat, and drink in the critical postoperative period 2, 3

The American Geriatrics Society Beers Criteria strongly advise against barbiturates in patients aged 65 and older, as they increase the risk of cognitive impairment, delirium, and falls 2, 3
Patients with severe hepatic impairment require extreme caution when taking Fioricet, as both butalbital and the acetaminophen component pose significant risks 5
Preoperative acetaminophen should be dose-adjusted according to the extent of hepatic resection in liver surgery 3

For regular users of Fioricet, ideally wean over 2 weeks preoperatively to prevent withdrawal, and continue medication perioperatively if weaning is impossible 1
Monitor closely for signs of withdrawal, including seizures, autonomic instability, and altered mental status, and consider phenobarbital substitution for withdrawal prophylaxis 1
Document total daily acetaminophen intake from all sources and adjust perioperative acetaminophen dosing to avoid exceeding 4000 mg daily 5

Daily use of Fioricet indicates treatment failure and warrants immediate therapy adjustment, as it carries the same clinical risks as scheduled barbiturates, including habit formation, tolerance, and dependence 5